FORTITUDE: Results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro).

Keytruda (pembrolizumab) - Merck (MSD)

NG-350A - PsiOxus

https://meetings.asco.org/abstracts-presentations/210233

Lee S. Rosen; D. Ross Camidge; Danny Khalil; Thomas Lillie; Jo Carter; David Krige; Jessica Davies; David Miles; Minesh Patel; Vladimir Evilevitch; Isabel Prieto González-Albo; Brian Champion; Aung Naing

Apr 28, 2022